Clinical Trials
20 trialsNCT04886804 2026-05-13
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT02609776 2026-05-08
CHRYSALIS
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03399799 2026-05-08
MonumenTAL-1
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03145181 2026-04-23
MajesTEC-1
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT02122913 2026-02-05
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
Bayer
Phase 1 Completed
NCT02715284 2026-01-13
GARNET
Tesaro, Inc.
Phase 1 Active not recruiting
NCT02074839 2025-06-08
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Servier
Phase 1 Recruiting
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT03416530 2025-02-14
ONC201 in Pediatric H3 K27M Gliomas
Jazz Pharmaceuticals
Phase 1 Terminated
NCT03665597 2025-02-10
KEYNOTE-555
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03212404 2025-02-03
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Phase 1 Active not recruiting
NCT01121588 2025-01-23
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Pfizer
Phase 1 Terminated
NCT02631044 2024-06-27
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT02081378 2024-03-18
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
Phase 1 Completed
NCT02564900 2024-01-22
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT02054806 2023-10-30
MK-3475-028
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02561988 2023-03-17
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Blueprint Medicines Corporation
Phase 1 Completed
NCT02508532 2022-06-21
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
Phase 1 Completed
NCT02097810 2021-06-09
STARTRK-1
Hoffmann-La Roche
Phase 1 Completed
NCT01077544 2020-12-29
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1 Completed